Immunovant data show potential for autoimmune disease drug
Bio Pharma Dive
SEPTEMBER 26, 2023
Much anticipated clinical trial data for Immunovant’s experimental FcRn inhibitor could catalyze business development decisions for its parent, Roivant Sciences.
Let's personalize your content